LDX Chart, page-770

Mate, you need to calm down. There would be a lot of people here who aren't in the green who aren't acting this way.

Sales literally have just started in the US and they have agreements in place. If you didn't note either, CLIA Waived is distributing the Febridx product through Thermo Fisher's subsidiary company Fisher Healthcare already. They are actively signing more agreements as we speak. Now, would you also think that if Henry Shein in the UK is our primary distribution partner in the UK/Europe an actively expanding the product reach via new countries being released, would they not be an obvious signup for the US as well? I would be very surprised if we didn't see an update about that at some stage.

One thing to note is that the US has one further benefit to that of Europe which is the rebates on product purchased. Europe doesn't have such arrangements on POC products and is available US. This is why sales would be substantially different between Europe v US etc. Uptake in the US would be less restrictive than the European market for this reason.

The hope with the product is that the US process is changed to have Febridx as the go to product for diagnosing at time of care, rather than flicking out a prescription for antibiotics etc.

The benefit here also is that there is a tangible product that we can directly correlate to revenue. We can see it being marketed, we can see if being sold unlike other companies. You cant also forget licencing of the product to other brands as well which is active as well.

Keep calm and enjoy your Christmas break! We may get an announcement from Santa or we wait for the new year and see where this is headed. No point selling for a loss out of spite.